BioLight will receive the right of first refusal on licensing ophthalmology technologies developed at the hospital.
BioLight Life Sciences Ltd. (TASE: BOLT) which deals in investment, development and commercialization for products to treat eye disorders, has announce agreement with Tel Aviv Sourasky Medical Center – Ichilov Hospital on finding and developing new technologies in ophthalmology. Under the agreement, BioLight will receive the right of first refusal for exclusive licenses on Ichilov Hospital developments. BioLight said that the agreement would enable it to expand and diversify its product portfolio through early-stage investment, and to create synergies between its portfolio companies.
RELATED ARTICLES
BioLight invests in US peripheral vision home test co
“BioLight is constantly working to expand its offering of technologies and products, through broadening the activity of its portfolio companies, and investment in promising new companies,” said BioLight CEO Yaacov Michlin. “Collaboration with Ichilov Hospital represents just part of this activity, and holds substantial potential for identifying new projects. The combination of the experience, know-how, and connections of BioLight with the technological innovation of Ichilov strengthens our status as the leading company in Israel in ophthalmology, with a strong and diverse portfolio.”
Published by Globes, Israel business news – en.globes.co.il – on November 30, 2021.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.
Tel Aviv Soursaky Medical Center – Ichilov Hospital credit: Tamar Matsafi
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
